Can deep phenotyping using retinal images predict response to intravitreal aflibercept therapy in patients with neovascular age-related macular degeneration?

Moorfields Eye Hospital0 个研究点目标入组 3,000 人开始时间: 2019年8月27日最近更新: 2023年8月2日

适应症

试验速览

2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37109349/ (added 17/07/2023)

•Inclusion criteria for both retrospective and prospective parts:
•1. Adults who are = 50 years and = 100 years
•2. Treatment naïve neovascular AMD at baseline
•3. Media clarity, pupillary dilation and patient cooperation for adequate imaging
•4. Ability to give informed consent
•Inclusion criteria for retrospective part only in addition to the above:
•1. Have received 3 loading injections of intravitreal aflibercept therapy at monthly intervals as per standard care
•2. Review up to 10 weeks after the 3rd loading dose with or without injection at this visit
•3. Had Heidelberg OCT at least at baseline and after the loading phase but ideally 4 Heidelberg OCTs for the 4 visits
•4. Heidelberg OCTA images if available for baseline and any visit thereafter (2nd, 3rd or 4th visit) provided there is a baseline OCTA (optional criteria)

•1. Co-existent ocular disease: any other ocular condition that, in the opinion of the investigator, might affect or alter visual acuity during the course of the study
•2. Any patient who has opted out of their information being used for research nationally or locally at any site

发起方